Gilead prepares for Chinese trials of antiviral after treating U.S. patient

As Gilead plans Chinese trials of remdesivir to treat the coronavirus, health authorities in Washington state reported that compassionate use of the nucleotide analog prodrug resolved almost all disease symptoms in one infected patient. The antiviral will join at least nine other trials under way in China for therapies to treat 2019-nCoV.

Sonia Choi, a spokesperson for Gilead Sciences Inc. (NASDAQ:GILD), told BioCentury the company expects to begin enrolling patients mid-February in two trials evaluating remdesivir to treat 2019-nCoV acute respiratory disease. ...